Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6417-6421

  Hull, Claire M ^a   Bader, Oliver ^b   Parker, Josie E ^a   Weig, Michael ^b   Gross, Uwe ^b   Warrilow, Andrew G S ^a   Kelly, Diane E ^a   Kelly, Steven L ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

14ALPHA METHYL 3,6 DIOL; 4,4 DIMETHYL CHOLESTA 8,24 DIENOL; AMPHOTERICIN B; DIMETHYL ZYMOSTEROL; EPISTEROL; ERGOSTA 5,7 DIENOL; ERGOSTA 5,8,22 TRIENOL; ERGOSTA 7 ENOL; ERGOSTA 7,22 DIENOL; ERGOSTA 8 ENOL; ERGOSTA 8,22 DIENOL; ERGOSTEROL; FECOSTEROL; LANOSTEROL; OBTUSIFOLIOL; STEROL DERIVATIVE; UNCLASSIFIED DRUG; ZYMOSTEROL;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA GLABRATA; GENE MUTATION; ISOMERIZATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

AMINO ACID SEQUENCE; AMPHOTERICIN B; ANTIFUNGAL AGENTS; AZOLES; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; PYRIMIDINES; SACCHAROMYCES CEREVISIAE; STEROID ISOMERASES; STEROLS; TRIAZOLES;

EID: 84869234407     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01145-12     Document Type: Article

References (32)

1. Bartlett MS, Eichholtz R, Smith JW. 1985. Antimicrobial susceptibility of Pneumocystis carinii in culture. Diagn. Microbiol. Infect. Dis. 3:381-387.
2. Bolard J. 1986. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim. Biophys. Acta 864:257-304.
3. Claudino ALR, et al. 2009. Mutants with heteroresistance to amphotericin B and fluconazole in Candida. Braz. J. Microbiol. 40:943-951.
4. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts (M27-A3), 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Ferrari S, et al. 2009. Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence. PLoS Pathog. 5:e1000268. doi:10.1371/journal.ppat.1000268.
6. Fidel PL, Jr, Vasquez JA, Sobel JD. 1999. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin. Microbiol. Rev. 12:80-96.
7. Geber A, et al. 1995. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother. 39:2708-2717.
8. Georgopapadakou NH, Walsh TJ. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. 40:279-291.
9. Gray KC, et al. 2012. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl. Acad. Sci. U. S. A. 109:2234-2239.
10. Hull CM, et al. 2012. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross resistance to azoles and amphotericin B. Antimicrob. Agents Chemother. 56:4223-4232.
11. James CS, Burden RS, Loeffler RST, Hargreaves JA. 1992. Isolation and characterization of polyene resistant mutants from the maize smut pathogen, Ustilago maydis, defective in ergosterol biosynthesis. J. Gen. Microbiol. 138:1437-1443.
12. Kanafani ZA, Perfect JR. 2008. Resistance to antifungal agents: mechanisms and clinical impact. Clin. Infect. Dis. 46:120-128.
13. Kelly SL, Lamb DC, Kelly DE, Loeffler J, Einsele H. 1996. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348:1523-1524.
14. 8-7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol. Lett. 122:39-42.
15. Krcmery V, Barnes AJ. 2002. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J. Hosp. Infect. 50:243-260.
16. 1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening. J. Med. Chem. 48:4754-4764.
17. Loffler J, et al. 1997. Molecular analysis of CYP51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol. Lett. 151:263-268.
18. Martel CM, et al. 2010. A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14α-demethylase) and ERG5 (encoding C22-desaturase) is cross-resistant to azoles and amphotericin B. Antimicrob. Agents Chemother. 54:3578-3583.
19. Martel CM, et al. 2010. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob. Agents Chemother. 54:4527-4533.
20. 197 of the human emopamil binding protein are required for in vivo sterol Δ8-Δ7 isomerization. Biochemistry 38:1119-1127.
21. Nguyen MH, et al. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
22. Pfaller MA, Messer SA, Hollis RJ. 1994. Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn. Microbiol. Infect. Dis. 20:127-133.
23. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727.
24. Rahier A, Pierre S, Riveill G, Karst F. 2008. Identification of essential amino acid residues in a sterol 8,7-isomerase from Zea mays reveals functional homology and diversity with the isomerases of animal and fungal origin. Biochem. J. 414:247-259.
25. Sabatelli F, et al. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015.
26. Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J. 2003. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob. Agents Chemother. 47:2404-2412.
27. Sanguinetti M, et al. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49:668-679.
28. Silve S, et al. 1996. The immunosuppressant SR 31747 blocks cell proliferation by inhibiting a steroid isomerase in Saccharomyces cerevisiae. Mol. Cell. Biol. 16:2719-2727.
29. Sterling TR, Merz WG. 1998. Resistance to amphotericin B: emerging clinical and microbiological patterns. Drug Resist. Updat. 1:161-165.
30. Tsai HF, et al. 2004. Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension. Antimicrob. Agents Chemother. 48:2483-2489.
31. Vandeputte P, et al. 2007. Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth. Antimicrob. Agents Chemother. 51:982-990.
32. Vandeputte P, et al. 2008. A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata. Antimicrob. Agents Chemother. 52:3701-3709.